HALO - Halozyme Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
HALO price evolution
HALO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $187.86 | $164.63 | $118.37 | |
| Short term investments | $341.17 | $298.82 | $217.63 | |
| Net receivables | $285.74 | $214.52 | $195.9 | $234.21 |
| Inventory | $131.41 | $159.31 | $168.54 | $127.6 |
| Total current assets | $1126.98 | $987.8 | $873.58 | $746.42 |
| Long term investments | ||||
| Property, plant & equipment | $74.49 | $75 | $78.07 | $74.94 |
| Goodwill & intangible assets | $854.17 | $871.94 | $889.7 | |
| Total noncurrent assets | $981.66 | $967.94 | $986.85 | |
| Total investments | $341.17 | $298.82 | $217.63 | |
| Total assets | $2118.03 | $1969.45 | $1841.53 | $1733.27 |
| Current liabilities | ||||
| Accounts payable | $12.4 | $15.43 | $13.32 | $11.82 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $108.81 | $133.36 | $131.64 | $112.49 |
| Long term debt | $1504.15 | $1502.52 | $1500.88 | $1499.25 |
| Total noncurrent liabilities | $1546.67 | $1532.08 | $1536.97 | |
| Total debt | $1502.52 | $1500.88 | $1499.25 | |
| Total liabilities | $1665.33 | $1680.03 | $1663.72 | $1649.46 |
| Shareholders' equity | ||||
| Retained earnings | $397.63 | $260.62 | $167.37 | $90.55 |
| Other shareholder equity | -$6.94 | -$2.07 | -$1.49 | -$9.28 |
| Total shareholder equity | $289.42 | $177.81 | $83.81 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $118.37 | $234.69 | $119.22 | $148.2 |
| Short term investments | $217.63 | $128.6 | $622.2 | $220.31 |
| Net receivables | $234.21 | $231.07 | $90.97 | $97.73 |
| Inventory | $127.6 | $100.12 | $53.91 | $60.75 |
| Total current assets | $746.42 | $739.01 | $926.29 | $554.76 |
| Long term investments | ||||
| Property, plant & equipment | $74.94 | $75.57 | $8.79 | $10.59 |
| Goodwill & intangible assets | $889.7 | $955.7 | ||
| Total noncurrent assets | $986.85 | $1102.5 | $178.14 | $25.16 |
| Total investments | $217.63 | $128.6 | $622.2 | $220.31 |
| Total assets | $1733.27 | $1841.51 | $1104.43 | $579.92 |
| Current liabilities | ||||
| Accounts payable | $11.82 | $17.69 | $1.54 | $1.93 |
| Deferred revenue | $5.5 | $4.28 | $5.77 | |
| Short long term debt | $13.33 | $89.42 | $397.23 | |
| Total current liabilities | $112.49 | $130.79 | $117.15 | $421.38 |
| Long term debt | $1499.25 | $1492.77 | $787.25 | |
| Total noncurrent liabilities | $1536.97 | $1540.92 | $790.33 | $7.49 |
| Total debt | $1499.25 | $1506.1 | $876.67 | $397.23 |
| Total liabilities | $1649.46 | $1671.71 | $907.48 | $428.88 |
| Shareholders' equity | ||||
| Retained earnings | $90.55 | $143.22 | -$58.91 | -$474.59 |
| Other shareholder equity | -$9.28 | -$0.92 | -$0.62 | $0.02 |
| Total shareholder equity | $83.81 | $169.8 | $196.95 | $151.05 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $290.08 | $231.35 | $195.88 | $230.04 |
| Cost of revenue | $39.61 | $28.33 | $52.3 | |
| Gross Profit | $240.66 | $191.75 | $167.55 | $177.74 |
| Operating activities | ||||
| Research & development | $21.04 | $19.11 | $21.34 | |
| Selling, general & administrative | $35.71 | $35.13 | $37.61 | |
| Total operating expenses | $77.46 | $74.51 | $72.01 | $76.71 |
| Operating income | $117.23 | $95.54 | $101.03 | |
| Income from continuing operations | ||||
| EBIT | $122.27 | $100.53 | $106.39 | |
| Income tax expense | $28.14 | $24.5 | $19.2 | $15.79 |
| Interest expense | $1.95 | $4.52 | $4.51 | $5.22 |
| Net income | ||||
| Net income | $137.01 | $93.25 | $76.82 | $85.39 |
| Income (for common shares) | $93.25 | $76.82 | $85.39 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $829.25 | $660.12 | $443.31 | $267.59 |
| Cost of revenue | $192.36 | $139.3 | $81.41 | $43.37 |
| Gross Profit | $636.89 | $520.81 | $361.9 | $224.23 |
| Operating activities | ||||
| Research & development | $76.36 | $66.61 | $35.67 | $34.24 |
| Selling, general & administrative | $149.18 | $143.53 | $50.32 | $45.74 |
| Total operating expenses | $299.32 | $253.28 | $86 | $79.97 |
| Operating income | $337.57 | $267.53 | $275.9 | $144.25 |
| Income from continuing operations | ||||
| EBIT | $367.09 | $265.87 | $256.04 | $149.68 |
| Income tax expense | $66.73 | $46.79 | -$154.19 | $0.22 |
| Interest expense | $18.76 | $16.95 | $7.53 | $20.38 |
| Net income | ||||
| Net income | $281.59 | $202.13 | $402.71 | $129.09 |
| Income (for common shares) | $281.59 | $202.13 | $402.71 | $129.09 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $93.25 | $76.82 | $85.39 | |
| Operating activities | ||||
| Depreciation | $20.33 | $20.21 | $20.69 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.47 | $9.87 | $9.66 | |
| Total cash flows from operations | $55.79 | $129.43 | $102.35 | |
| Investing activities | ||||
| Capital expenditures | -$2.58 | -$3.54 | -$2.6 | |
| Investments | -$39.46 | -$79.14 | -$5.7 | |
| Total cash flows from investing | -$292.2 | -$42.04 | -$82.68 | -$8.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.99 | -$249.92 | ||
| Net borrowings | ||||
| Total cash flows from financing | $27.55 | $9.48 | -$0.49 | -$249.92 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $35.95 | $23.24 | $46.26 | -$155.86 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $281.59 | $202.13 | $402.71 | $129.09 |
| Operating activities | ||||
| Depreciation | $84.86 | $49.64 | $3 | $3.28 |
| Business acquisitions & disposals | -$999.12 | |||
| Stock-based compensation | $36.62 | $24.4 | $20.82 | $17.2 |
| Total cash flows from operations | $388.57 | $240.11 | $299.44 | $55.45 |
| Investing activities | ||||
| Capital expenditures | -$15.29 | $21.2 | -$1.46 | -$1.43 |
| Investments | -$81.61 | $490.92 | -$404.83 | $79.78 |
| Total cash flows from investing | -$96.91 | -$487 | -$406.29 | $78.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$394.5 | -$185.95 | -$337.52 | -$86.72 |
| Net borrowings | -$13.48 | $617.44 | $415.39 | -$19.56 |
| Total cash flows from financing | -$407.99 | $362.37 | $77.86 | -$106.28 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$116.33 | $115.48 | -$28.98 | $27.52 |
News
Fundamentals
| Market cap | $7.41B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 127.18M |
| Revenue | $947.36M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $392.47M |
| Revenue Q/Q | 34.28% |
| Revenue Y/Y | 21.35% |
| P/E ratio | 18.89 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 7.83 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $3.09 |
|---|---|
| ROA | 20.49% |
| ROE | N/A |
| Debt/Equity | 19.68 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.36 |
| Quick ratio | 9.15 |